JPMorgan Funds - Europe Equity Plus Fund C (perf) (acc) - USDRegister to Unlock Ratings |
Performance History | 31/08/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | -1.7 | 24.9 | -1.8 | 11.9 | 14.2 | |
+/-Cat | -6.0 | 9.6 | 6.5 | 0.3 | 6.8 | |
+/-B’mrk | -4.3 | 7.3 | 2.8 | -1.3 | 5.0 | |
Category: Europe Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar DM Eur TME NR EUR |
Key Stats | ||
NAV 26/09/2024 | USD 273.20 | |
Day Change | 0.07% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
ISIN | LU0982976267 | |
Fund Size (Mil) 26/09/2024 | EUR 1987.33 | |
Share Class Size (Mil) 26/09/2024 | USD 11.51 | |
Max Initial Charge | - | |
Ongoing Charge 18/07/2024 | 1.04% |
Investment Objective: JPMorgan Funds - Europe Equity Plus Fund C (perf) (acc) - USD |
To provide long term capital growth through exposure to European companies, by direct investments in securities of such companies and through the use of derivatives. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Nicholas Horne 01/05/2010 | ||
Ben Stapley 31/01/2017 | ||
Click here to see others | ||
Inception Date 15/11/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for JPMorgan Funds - Europe Equity Plus Fund C (perf) (acc) - USD | 31/08/2024 |
|
|
Top 5 Holdings | Sector | % |
JPM EUR lqdty LVNAV X (T0 acc.) | 5.16 | |
Novo Nordisk A/S Class B | Healthcare | 4.26 |
ASML Holding NV | Technology | 3.30 |
Novartis AG Registered Shares | Healthcare | 3.02 |
SAP SE | Technology | 2.50 |
Increase Decrease New since last portfolio | ||
JPMorgan Funds - Europe Equity Plus Fund C (perf) (acc) - USD |